Get started
Author

Volker Heinemann

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
2025 · Kohei Shitara, Sun Young Rha, et al. · Journal of Clinical Oncology · 56
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
2025 · Gilles Rademaker, Grace A. Hernandez, et al. · Nature · 51
PDF
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
2024 · Romain Cohen, Morteza Raeisi, et al. · European Journal of Cancer · 22
PDF
Leopard-like vitiligo with capecitabine
2001 · Monika-H Schmid-Wendtner, Clemens-M Wendtner, et al. · The Lancet · 16
PDF
FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.
2025 · Lena Weiss, Volker Heinemann, et al. · Journal of Clinical Oncology · 11
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE ‐4.5 study
2024 · Susanne Klein‐Scory, Alexander Baraniskin, et al. · Molecular Oncology · 11
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
2025 · Lena Weiss, Sebastian Stintzing, et al. · European Journal of Cancer · 10
PDF
Closing the cancer care gap with a patient-reported nutrition screening: A retrospective analysis of a quality improvement project on an oncology ward (CCC study)
2023 · Nicole Jost, Nicole Erickson, et al. · Clinical Nutrition ESPEN · 8
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial
2025 · Kathrin Heinrich, Sebastian Stintzing, et al. · European Journal of Cancer · 6
PDF
Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
2025 · Klara Dorman, Christoph J. Auernhammer, et al. · Targeted Oncology · 4
PDF
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
2026 · Sylvie Lorenzen, Thorsten Oliver Goetze, et al. · Nature Communications · 3
PDF
The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?
2026 · Wolfram C. M. Dempke, Christoph Sippel, et al. · Future Oncology · 1
Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic Cancer
2026 · Hannah Randeu, Abel Bronkhorst, et al. · Cells · 1
PDF
Liver transplantation in metastatic colorectal cancer: a new standard of care?
2024 · Volker Heinemann, Sebastian Stintzing · The Lancet · 1
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation
2024 · Nabeel Mansour, Kathrin Heinrich, et al. · Cancer Imaging · 1
PDF
A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.
2024 · Salah-Eddin Al-Batran, Sylvie Lorenzen, et al. · Journal of Clinical Oncology · 1
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
2026 · Makoto Ueno, Makoto Ueno, et al. · EClinicalMedicine
Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer
2026 · Sai Agash Surendran, Michael Guenther, et al. · European Journal of Cancer
PDF
Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial
2026 · Tshilidzi M. Klingler, Uwe M. Martens, et al. · European Journal of Cancer
PDF
Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial
2026 · Michael Masetti, Alexander Nieto, et al. · European Journal of Cancer
PDF
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control arms
2026 · Morteza Raeisi, Thierry André, et al. · JNCI Journal of the National Cancer Institute
Early-onset kolorektales Karzinom in der Schwangerschaft: fortgeschrittene Stadien, begrenzte Evidenz und individualisierte Therapiestrategien – eine monozentrische Fallserie
2026 · F Scholz, T Starrach, et al. · Zeitschrift für Gastroenterologie
Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis
2026 · Manuel Valladares-Ayerbes, Pilar García Alfonso, et al. · Journal of Gastrointestinal Oncology
4RO Chemotherapy (CT) plus anti-EGFR retreatment versus CT switch plus anti-VEGF/R after progression in pMMR/MSS, RAS/BRAF wild-type metastatic colorectal cancer (mCRC): Individual patient data analysis of 5 randomized trials (RCTs)
2026 · V. Studiale, M.M. Germani, et al. · Annals of Oncology
PDF
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials
2026 · Kenta Iguchi, Kentaro Yamazaki, et al. · European Journal of Cancer
Works count: 50
Citation count: 203
H-index: 8
I10-index: 7
Year
Topic
Type